This Week’s Reversal Watchlist
Prices referenced below are as of the prior market close. All stage evaluations reflect data current as of the date of this post.
What the Screen Surfaced This Week
Every week, we run a systematic screen looking for stocks that have been hit hard enough — and are large enough, liquid enough, and fundamentally sound enough — to warrant a closer look as potential reversal candidates. The criteria are straightforward: RSI below 30, down 20% or more from highs, market cap above $1 billion, Buy or better analyst consensus, and average daily volume above 500K shares.
This week’s screen returned two new names: Boston Scientific (BSX) and Blue Owl Capital (OWL). We also evaluated the four names from our March 25 watchlist — Wingstop, Microsoft, Dollar General, and Cintas — for carry-over status.
Here’s what the full triage looked like, stage by stage.
The Macro Backdrop (Stage 3 Context)
Before diving into individual names, the broader market environment deserves acknowledgment — because it sets the bar for everything else.
The S&P 500 officially entered correction territory in late March, dropping roughly 10% from its January peak. The drivers are a combination of new U.S. tariffs averaging 12–14%, Brent crude spiking above $100 per barrel on Middle East tensions, and a Federal Reserve that is stuck in a difficult position between supply-driven inflation and a cooling labor market. SPY is trading below its 200-day moving average with no clear stabilization yet.
This matters for how we think about Stage 4 confirmation. In a healthy or recovering market, a higher-low formation or moving average reclaim is enough signal. In the current environment, the bar is meaningfully higher — we want to see confirmation that holds, not just a reflexive bounce in a still-declining tape. Patience is not inactivity. It’s how you avoid buying the first bounce in a downtrend.
With that as context, here’s how every name on the board this week fared.
Full Stage-by-Stage Triage
| Ticker | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Status |
|---|---|---|---|---|---|
| WING | ✅ | ✅ | ⚠️ Macro headwind | ❌ Not yet | Tier 1 — Watchlist |
| MSFT | ✅ | ✅ | ⚠️ Macro headwind | ❌ Not yet | Tier 2 — Monitor |
| DG | ✅ | ✅ | ⚠️ Tariff exposure | ❌ Range midpoint | Tier 2 — Monitor (downgraded) |
| BSX | ✅ | ❌ Active litigation + segment deterioration | — | — | Eliminated |
| OWL | ✅ | ❌ Redemption gating + structural issues | — | — | Eliminated |
| CTAS | ✅ | ❌ Major acquisition in progress | — | — | Eliminated |
Names Eliminated This Week
Boston Scientific (BSX) — Eliminated at Stage 2
BSX hit the screen on paper: down roughly 43% from its 52-week high of $109.50, trading near $62 — essentially at a fresh 52-week low as of this week, with a market cap above $90 billion and analyst sentiment that remains constructive. On raw screener metrics, it looks like exactly the kind of oversold large-cap that warrants a look.
The Stage 2 review stopped it cold.
On February 4, 2026, Boston Scientific reported Q4 results and disclosed that its U.S. Electrophysiology segment was experiencing slower-than-expected market growth and intensifying competition. The stock fell 17.6% in a single session. In the weeks that followed, multiple securities class action lawsuits were filed, with the core allegation being that management made materially misleading statements about the sustainability of U.S. EP growth — and that executives were aware the segment was approaching a tipping point earlier than the market had been led to believe. The lead plaintiff deadline is May 4, 2026, and the litigation is active.
This isn’t a case of a stock that got hit on bad sentiment while the business stayed intact. The core U.S. EP segment — the growth engine that powered BSX’s premium valuation — is the subject of both an operational disappointment and an active fraud allegation. Those two things together represent exactly the kind of Stage 2 disqualifier this framework exists to catch. The question in a reversal setup is always: is the sell-off an overreaction to temporary noise, or is it reflecting something real? Here, the answer appears to be something real.
BSX remains on our radar. If the litigation resolves, the EP business stabilizes, and the stock finds a floor at current levels, this could become a compelling setup down the road. For now, it’s a pass.
Eliminated: Active legal issues and fundamental deterioration in the core growth segment.
Blue Owl Capital (OWL) — Eliminated at Stage 2
OWL is down roughly 60% from its 52-week high of $21.08, trading near $8.45, with a market cap still above $13 billion. Volume is robust. On paper, this is a screamer — a large, well-known alternative asset manager cut in half, with Buy ratings still on the books at several shops.
The Stage 2 review revealed why the market is right to be cautious.
In early April, Blue Owl announced it was capping redemptions at 5% across two of its private credit funds after receiving approximately $5.4 billion in withdrawal requests. Separately, the company’s private credit funds had just posted their worst monthly losses since 2022. A shareholder lawsuit has also been filed.
Capping redemptions is a meaningful signal. It means investors in those funds — large institutional allocators — tried to exit and couldn’t. That’s not a stock sentiment story. That’s a structural crisis of confidence in the underlying product. Blue Owl’s business is built on the trust of capital allocators. When that trust breaks down enough to trigger a gate, the recovery path is long and uncertain — not the kind of near-term mean reversion setup this framework is designed to find.
The stock is cheap in an absolute sense. That doesn’t mean it’s not going lower, and it doesn’t mean the reversal is imminent.
Eliminated: Active redemption gating, structural product deterioration, pending litigation.
Cintas (CTAS) — Eliminated at Stage 2 (Dropped from Prior Watchlist)
CTAS has been on our watchlist since March 25. The original thesis was straightforward: a high-quality compounder with record margins, down 27% from its 52-week high, trading near multi-year lows. The franchise model, route density, and customer retention metrics were all intact. We were waiting on Stage 4 confirmation.
That thesis changed materially in mid-March when Cintas announced a $5.5 billion deal to acquire UniFirst, agreeing to pay $310 per share in cash and stock, with management projecting $375 million in operating cost synergies. The stock has since drifted closer to its 52-week low, now trading around $172, within roughly 4% of the $165.60 floor.
We want to be direct about why this changes things: the Cintas we put on the watchlist was a clean compounder in mean-reversion territory. The Cintas that exists today is a company absorbing a $5.5 billion acquisition in an uncertain macro environment. Those are different investments. The risk is no longer “will sentiment recover?” — it’s “will this integration go as planned, and on what timeline?” That’s a legitimate thesis for some investors, but it’s not a reversal setup under our framework.
This is the same logic that caused us to pass on MKC after the Unilever deal announcement. Deal and restructuring events shift the fundamental character of a setup. We don’t try to trade through them.
CTAS is not off our radar permanently. If the deal closes cleanly, synergies come in on schedule, and the stock is still depressed, that’s a different conversation. For now, it comes off the active watchlist.
Eliminated: Major acquisition introduces integration risk that changes the risk profile of the setup.
This Week’s Watchlist Name
Wingstop (WING) — Tier 1 Watchlist (Multi-Week Carry-Over)
This is WING’s third consecutive appearance on the watchlist. It was first flagged on our March 25 post and carried into April. Here’s what has changed — and what hasn’t.
What changed since March 25: The stock made a new 52-week low of approximately $144.68 in early April, extending the drawdown from its 52-week high of $388.14 to roughly 63%. It has since bounced and was trading near $155–163 as of this writing, though the range has been volatile. Citi Research issued a fresh upgrade to Buy with a $230 price target, joining a growing list of Wall Street firms that have maintained or upgraded their stance despite the selloff. Wells Fargo kept its Overweight rating while trimming its target to $225 from $330. Raymond James upgraded to Strong Buy. The average analyst price target now sits around $300, implying approximately 85–90% upside from current levels, with 27 out of 27 analysts rating the stock Buy or better.
The setup in brief:
Wingstop is a capital-light, franchise-first restaurant model that spent most of the past three years as one of the highest-valued names in the restaurant sector. The selloff is real and the near-term headwinds are real. Domestic same-store sales turned negative, falling 5.8% in Q4 2025. Consumer sentiment — especially among lower-income and Hispanic households, which over-index in WING’s customer base — has weakened. These aren’t manufactured concerns.
But the structural story underneath the comp decline is worth examining carefully:
- Unit growth is intact and accelerating. Wingstop opened a record 493 net new restaurants in fiscal 2025, reaching 3,056 locations globally. 2026 guidance calls for 15–16% global unit growth — a meaningful acceleration from the company’s historical ~10% algorithm.
- The asset-light model means franchisee pain doesn’t directly transfer to the corporate P&L. System royalties are more stable than company-owned restaurant revenue.
- Smart Kitchen rollout is complete. The new technology platform deployed across U.S. locations is expected to drive margin improvements through labor and operational efficiency in 2026.
- International expansion is early and growing. A landmark agreement for India was recently announced, adding a new long-duration growth vector.
- Earnings beat in Q4 2025. Adjusted EPS of $1.00 beat consensus of $0.84 by 19%. The underlying profitability picture is not broken.
The bear case is real and should not be dismissed. Domestic comps negative for the first time in years. Consumer softness in the core demographic. A macro environment that is actively pressuring discretionary spending. If tariff uncertainty and oil prices persist, there is no guarantee the comp story improves in the next one or two quarters. This is not a guaranteed setup — it is a setup with defined risk.
Technical picture: WING is trading roughly 60% below both the 50-day and 200-day moving averages, which is a testament to how severe the selloff has been. The stock has begun to base near the $144–155 range, which represents a cluster of support going back to early 2023. The April 29 earnings report is now the most important near-term event.
Stage 4 triggers we’re watching:
The setup doesn’t become an alert until one of these fires:
- MA reclaim: A daily close above the declining 20-day moving average (currently near $175–180) on above-average volume would be the first meaningful technical signal.
- Catalyst resolution: Q1 2026 earnings on April 29. If domestic comps show sequential improvement from -5.8%, or if management provides evidence the Smart Kitchen platform is showing up in margins, that resolves the primary fundamental overhang.
- Higher-low formation: A weekly close above the prior bounce high (~$167) after holding the April lows (~$144) would establish the first higher-low structure since the breakdown.
Until one of these fires, WING stays on the watchlist — not in the portfolio.
Risk-reward as staged:
| Scenario | Price Level | From ~$155 |
|---|---|---|
| Stop (below April lows) | ~$140 | -10% |
| Target 1 (first resistance) | ~$200 | +29% |
| Target 2 (analyst consensus) | ~$300 | +94% |
| Target 3 (prior highs area) | ~$388 | +150% |
Using $140 as a stop, the ratio to Target 1 alone is approximately 2.9:1. The ratio to analyst consensus is north of 9:1. Those are the kinds of numbers that make this worth continued patience — but only if Stage 4 confirms.
Next event: Q1 2026 earnings — April 29, 2026.
Tier 2 Monitor: Names We’re Watching But Not Publishing
Microsoft (MSFT)
MSFT has been in our Tier 2 monitor column since March 25. The fundamental case is clean — Azure cloud growth, Copilot commercial traction (management reportedly hit internal sales targets ahead of schedule), and a position at the center of enterprise AI spending. The stock is down roughly 33% from its 52-week high of $555.45, trading around $370–381, within approximately 6% of its 52-week low.
Stage 2 is clean. No fundamental deterioration, no legal issues, no revenue decline. Stage 3 is the concern — the macro regime is actively working against tech multiple expansion, and MSFT’s valuation, while more attractive than a year ago, doesn’t scream distressed.
What we’re waiting for: Q3 FY2026 earnings (likely late April) will be the first real opportunity for a catalyst resolution event. If Azure growth reaccelerates and Copilot revenue is visible in the numbers, that could serve as the trigger. Until then, the stock has no technical confirmation — it is trending lower on declining volume with no base forming.
Still watching. Not yet publishable as a watchlist name.
Dollar General (DG)
DG was added to the March 25 watchlist as a near-52-week-low setup. It was trading around $84–90 at the time. It has since rebounded to roughly $121 — about 43% off its lows — and now sits in the middle of its 52-week range of $84.70–$158.23.
The rebound is encouraging in one sense: the market found the prior lows to be a reasonable floor. But a stock that has bounced 40%+ is no longer in the same risk-reward position it was two weeks ago. We’re now at a point where the upside to analyst targets (~$148 average) is around 22%, and the downside to the prior support zone is around 30%. That’s an inverted or flat ratio — not a watchlist-quality setup.
The tariff exposure also complicates the picture. Dollar General sources a significant share of its inventory from China and other markets subject to elevated tariffs. New CEO Todd Vasos has outlined an operational turnaround and store expansion plan, but executing it in a 12–14% tariff environment is a material headwind.
We’re downgrading DG to Tier 2 monitor. If it pulls back to the $100–110 range and builds a base there, the setup becomes interesting again. For now, the risk-reward doesn’t qualify.
Downgraded to monitor. Looking for a pullback toward prior support before re-engaging.
The Bottom Line
Two new names screened in this week. Both were eliminated at Stage 2 — one for active litigation and segment-level fundamental impairment, one for a structural redemption crisis in its core product. One prior watchlist name (CTAS) was dropped for a deal-driven change in investment character.
WING is the sole active Tier 1 name. The setup continues to mature, the bear case is real but bounded, and the April 29 earnings report is the next gate. We’re watching, we’re patient, and we will publish an alert when Stage 4 confirms — not before.
As always, nothing in this post constitutes investment advice. Position sizing and entry decisions are yours to make. Our job is to surface the setups, document the reasoning, and be honest when confirmation hasn’t arrived yet.
Direction Alerts publishes weekly watchlist posts and stage-gated alerts. Watchlist posts identify Stage 1 candidates under evaluation — no entry recommendation is implied. Alerts are published only when Stages 1–4 have been fully cleared. Past watchlist performance is tracked publicly on our portfolio page. This content is for educational and informational purposes only.